Roche's Phase III STARGLO study demonstrates Columvi significantly extends survival in ...

Retrieved on: 2024-06-15 20:51:53

Tags for this article:

Click the tags to see associated articles and topics

Roche's Phase III STARGLO study demonstrates Columvi significantly extends survival in .... View article details on hiswai:

Excerpt

D., Roche's Chief Medical Officer and Head of Global Product Development. “Moreover, patients do not have to wait to start treatment with Columvi.

Article found on: www.kauppalehti.fi